Polyarteritis nodosa

1. High-Yield Summary

Polyarteritis nodosa (PAN) is a severe, life-threatening systemic necrotizing vasculitis that predilectively targets medium- and small-sized muscular arteries. A critical diagnostic hallmark is its strict sparing of the pulmonary circulation and microvasculature (arterioles, capillaries, and post-capillary venules), distinguishing it fundamentally from microscopic polyangiitis and other small-vessel vasculitides.

• The Cardinal Clinical Phenotype: Systemic PAN classically manifests with constitutional decline (prolonged fever, night sweats, fatigue, weight loss > 4 kg), rapidly progressive asymmetric mononeuritis multiplex (foot drop or wrist drop in 50% to 70%), renovascular hypertension, ischemic abdominal pain ("intestinal angina"), and cutaneous stigmata (livedo reticularis, subcutaneous tender nodules, digital ischemia, and deep ulcerations).
• Strict ANCA Negativity: Classic PAN is strictly seronegative for antineutrophil cytoplasmic antibodies (ANCA). Any detection of myeloperoxidase (MPO-ANCA) or proteinase-3 (PR3-ANCA) strongly indicates microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA), demanding diagnostic re-evaluation. A subset of secondary cases is triggered by hepatitis B virus (HBV) infection or, in children and young adults, monogenic deficiency of adenosine deaminase 2 (DADA2).
• Gold Standard Diagnostic Modalities: Definitive diagnosis requires either histopathologic demonstration of focal, transmural necrotizing arteritis with fibrinoid necrosis and mixed leukocytic infiltration in a symptomatic tissue (combined sural nerve/gastrocnemius biopsy, deep full-thickness skin biopsy, or testicular biopsy) or angiographic visualization of multiple saccular or fusiform microaneurysms (1 to 5 mm) and branch stenoses in the renal, celiac, or mesenteric arterial arborizations.
• Risk-Stratified Induction Regimen: Treatment intensity is dictated by the validated Five-Factor Score (FFS). Non-severe PAN (FFS = 0) is treated with high-dose oral glucocorticoids (prednisone 1 mg/kg/day) combined with non-cyclophosphamide disease-modifying agents (methotrexate or azathioprine). Severe, organ- or life-threatening PAN (FFS ≥ 1, manifesting mesenteric, renal, cardiac, or progressive central/peripheral neurologic disease) mandates immediate intravenous pulse methylprednisolone followed by pulsed intravenous cyclophosphamide.
• The Surgical Revascularization Contraindication: Direct open vascular reconstruction across acutely inflamed, necrotic arterial segments is strictly contraindicated due to friable vessel walls, inevitable suture line disruption, and fatal anastomotic rupture. Active intra-abdominal hemorrhage from ruptured renal or mesenteric microaneurysms must be treated primarily with transcatheter arterial embolization (TAE). Dry digital gangrene requires nonoperative demarcation under systemic immunosuppression rather than early surgical amputation.

2. Anatomy

A rigorous understanding of the vascular caliber, branching topology, and neuromuscular danger zones is essential for establishing an accurate histopathologic diagnosis and avoiding catastrophic surgical misadventures in polyarteritis nodosa.

Medium-Sized Muscular Arterial Architecture

Polyarteritis nodosa preferentially attacks medium-caliber muscular visceral and somatic arteries (luminal diameter typically ranging from 0.5 to 1.0 mm) and small parenchymal arteries:

• Trilaminar Vessel Wall Anatomy: The target muscular artery comprises a luminal tunica intima (endothelium and internal elastic lamina), a robust tunica media containing multiple circumferential layers of smooth muscle cells bounded externally by the external elastic lamina, and an outer tunica adventitia composed of collagenous connective tissue, fibroblasts, and the vasa vasorum.
• Predilection for Bifurcations: Inflammatory disruption localizes predominantly to arterial branch points and bifurcation crests, where hemodynamic shear stress accelerates immune complex deposition and leukocyte adhesion.
• Microvascular Exemption: Unlike microscopic polyangiitis, Henoch-Schönlein purpura (IgA vasculitis), or hypersensitivity vasculitis, PAN strictly spares post-capillary venules, true capillaries, and pre-capillary arterioles. Consequently, immune-mediated necrotizing glomerulonephritis and alveolar capillaritis (diffuse pulmonary hemorrhage) do not occur in primary PAN.

Neurovascular Danger Zones and Biopsy Corridors

Obtaining an adequate tissue biopsy is the primary orthopaedic surgical intervention. Precise knowledge of the anatomical planes and structures at risk is required:

• Sural Nerve and Gastrocnemius Biopsy Corridor: The sural nerve is formed by the union of the medial sural cutaneous nerve (branch of tibial nerve) and the peroneal communicating branch (branch of common fibular nerve). It descends in the posterior lower calf immediately lateral to the lesser saphenous vein, piercing the crural fascia at the mid-calf before coursing behind the lateral malleolus. An open incisional biopsy must sample both the sural nerve and the adjacent medial gastrocnemius or peroneus brevis muscle belly. Danger zones include the lesser saphenous vein (risk of laceration and hematoma) and the lateral calcaneal branches (which cause painful heel neuroma if transected distally).
• Superficial Peroneal Nerve and Peroneus Brevis Muscle Corridor: Positioned in the lateral leg compartment, the superficial peroneal nerve courses between the peroneus longus and brevis muscles before penetrating the deep crural fascia approximately 10 to 12 cm proximal to the tip of the lateral malleolus. Biopsy of the nerve and muscle branches provides high sensitivity for vasculitic neuropathy; inadvertent injury to the main trunk produces permanent sensory loss over the anterolateral distal leg and dorsal foot.
• Acral Extremity Digital End-Arteries: Common and proper digital arteries in the hands and feet become thrombosed secondary to intense necrotizing arteritis of the palmar and plantar arches. These vessels are terminal end-arteries without adequate collateral cross-flow. Debriding or incising ischemic digits during active vasculitis precipitates catastrophic proximal progression of tissue necrosis.

Visceral and Renal Vascular Arborization

Visceral ischemia accounts for the majority of fatalities in untreated PAN:

• Renal Arborization: Vasculitis involves the main lobar, interlobar, and arcuate arteries. Ischemia leads to multiple cortical wedge infarcts, renin hypersecretion, and malignant systemic hypertension. Because the glomerular capillaries are spared, nephritic urinary sediment and immune complex glomerulonephritis are absent.
• Mesenteric and Celiac Arteries: Branches of the superior mesenteric artery (jejunal, ileal, and ileocolic branches) and celiac axis undergo segmental transmural destruction. Microaneurysm rupture causes life-threatening retroperitoneal or intraperitoneal hemorrhage, while transmural thrombosis results in patchy, ischemic bowel infarction and perforation.

3. Pathogenesis

The pathogenesis of polyarteritis nodosa represents a complex cascade of immune-mediated endothelial damage, segmental transmural inflammation, and destructive remodeling of the muscular arterial wall.

Immune Complex Deposition and Endothelial Injury

In secondary PAN associated with hepatitis B virus infection, circulating HBsAg-anti-HBs antibody immune complexes deposit in the subendothelial space of medium-caliber muscular arteries, particularly at bifurcation points where turbulent shear stress is maximal. These deposited immune complexes activate the classical complement cascade, generating potent anaphylatoxins (C3a and C5a) that recruit and activate circulating neutrophils and monocyte-macrophages. In idiopathic PAN, cell-mediated cytotoxicity directed against endothelial antigens drives an identical vascular injury pattern independent of viral antigenemia.

Transmural Fibrinoid Necrosis and Microaneurysm Formation

The histopathologic evolution follows distinct morphological phases:

• Acute Phase: Neutrophils and mononuclear leukocytes infiltrate all three layers of the arterial wall (panarteritis). Activated neutrophils release lysosomal enzymes, reactive oxygen species, and neutrophil extracellular traps (NETs), causing catastrophic proteolytic digestion of the internal and external elastic laminae. Plasma proteins, notably fibrinogen, leak into the necrotic vessel media and polymerize into dense, eosinophilic, amorphous deposits termed fibrinoid necrosis.
• Destructive Phase: Loss of structural muscular integrity and fragmentation of the internal elastic lamina weaken the arterial wall against systolic intravascular hydrostatic pressure. The thinned, necrotic wall bulges outward, forming characteristic saccular or fusiform microaneurysms measuring 1 to 5 mm in diameter. Secondary endothelial ulceration precipitates localized platelet aggregation and non-occlusive or occlusive thrombosis.

Healing, Fibrosis, and Luminal Obliteration

As the acute neutrophil-predominant infiltrate subsides, it is replaced by an adventitial and intimal fibroblastic repair response. Proliferation of myofibroblasts and dense collagen deposition within the tunica intima produce severe luminal narrowing and concentric fibro-obliteration. Because the vasculitic insult is segmental, normal arterial segments alternate with segments of nodular adventitial fibrosis and microaneurysmal dilatation, generating the classical "rosary bead" or "string-of-beads" gross macroscopic appearance that historically gave the disease its name.

4. Natural History

Without therapeutic intervention, polyarteritis nodosa is a rapidly fatal systemic disorder. Modern pharmacologic management has dramatically transformed its clinical trajectory from an acute lethal illness into a manageable chronic inflammatory disorder.

Epidemiology and Demographics

Primary idiopathic PAN is a rare orphan disease with an estimated annual incidence of 2 to 9 cases per million individuals in Europe and North America, and a point prevalence of 30 to 50 cases per million. The disease affects males slightly more frequently than females (male-to-female ratio approximately 1.5:1). Although it can occur at any age, the peak age of onset is between 40 and 60 years. In contrast, pediatric-onset PAN or systemic vasculitis developing in the first two decades of life frequently represents monogenic deficiency of adenosine deaminase 2 (DADA2). The widespread implementation of universal recombinant hepatitis B vaccination programs has resulted in a marked global decline in HBV-associated PAN over recent decades.

Natural Progression and Untreated Mortality

In historical cohorts prior to the introduction of systemic corticosteroid therapy, polyarteritis nodosa was almost universally fatal, with a 5-year survival rate of less than 13%. Patients succumbed rapidly to fulminant intra-abdominal complications (massive mesenteric infarction, bowel gangrene, or bowel perforation), intracranial hemorrhage from ruptured cerebral microaneurysms, intractable malignant renovascular hypertension culminating in hypertensive encephalopathy and acute heart failure, or secondary bacterial sepsis.

Contemporary Prognosis and Relapse Patterns

The introduction of combined high-dose glucocorticoid and pulse cyclophosphamide therapy has raised overall 5-year survival to greater than 80% to 85%, and 10-year survival to approximately 72% to 75%. Baseline mortality risk is accurately stratified by the French Vasculitis Study Group Five-Factor Score (FFS). Relapse occurs in approximately 20% to 30% of patients with idiopathic PAN, usually during glucocorticoid tapering or following cyclophosphamide cessation. In contrast, successfully treated HBV-associated PAN exhibits a remarkably low relapse rate (< 5%) once complete viral clearance and HBsAg seroconversion are achieved.

5. Clinical Presentation

The presentation of polyarteritis nodosa is notoriously protean, reflecting widespread, unpredictable medium-artery ischemia across multiple organ systems.

History

Patients present with an insidious or subacute combination of constitutional, neurologic, musculoskeletal, and gastrointestinal symptoms:

• Constitutional Prostration: Unexplained prolonged fever of unknown origin (> 38.0°C), profound generalized fatigue, night sweats, and rapid unintentional weight loss exceeding 4 kg (often > 10% of total body weight).
• Neurologic Complaints: Sudden onset of asymmetric numbness, burning dysesthesias, or motor weakness in an isolated peripheral nerve distribution (e.g., sudden unilateral foot drop or inability to extend the fingers and wrist), characteristic of mononeuritis multiplex. As additional nerve trunks succumb to vasa nervorum infarction, the deficits become confluent, mimicking a generalized polyneuropathy.
• Musculoskeletal Aches: Severe, unremitting, non-articular myalgias predilectively involving the calves and thighs, frequently exacerbated by ambulation. Migratory arthralgias affect large joints (knees, ankles, elbows) without frank inflammatory effusions or erosive joint destruction.
• Gastrointestinal and Urologic Warning Signs: Postprandial diffuse periumbilical abdominal pain ("intestinal angina") developing 30 to 60 minutes after eating, associated with anorexia and progressive fear of eating. Acute unilateral testicular or epididymal pain and swelling without prior trauma or infectious exposure is a classic presentation in males.

Physical Examination

Systematic physical examination must evaluate dermatologic, neurologic, vascular, and musculoskeletal compartments:

• Cutaneous Signs: Inspect the lower extremities, thighs, and buttocks for livedo reticularis (a violaceous, net-like, reticulated vascular pattern that does not blanch with warm compression), palpable erythematous subcutaneous nodules along the superficial course of arteries (frequently exquisitely tender), deep punch-out cutaneous ulcerations with undermined borders, and digital cyanosis or necrotic eschars.
• Targeted Neuromuscular Mapping: Rigorously assess individual peripheral nerves for asymmetric sensorimotor deficits indicative of mononeuritis multiplex.

6. Imaging and Diagnostic Studies

Because no single pathognomonic laboratory test exists, confirmation of polyarteritis nodosa relies upon a disciplined diagnostic hierarchy integrating serology, cross-sectional or catheter angiography, electrodiagnosis, and targeted histopathology.

Laboratory Biomarkers and Serologic Profile

Laboratory testing reflects intense systemic inflammation and rules out alternative vasculitides:

• Acute-Phase Reactants: Erythrocyte sedimentation rate (ESR) is markedly elevated, typically exceeding 50 to 80 mm/hr. Serum C-reactive protein (CRP) is substantially elevated (> 50 mg/L) in active untreated disease. Normal inflammatory markers strongly argue against active untreated systemic PAN.
• Hematologic Parameters: Normocytic, normochromic anemia of chronic disease is present in over 75% of patients. Marked reactive leukocytosis with prominent neutrophilia (white blood cell count 15,000 to 25,000/µL) and reactive thrombocytosis (platelets > 500,000/µL) are typical. Peripheral eosinophilia is generally absent or minimal; pronounced eosinophilia (> 1,500/µL) mandates immediate investigation for eosinophilic granulomatosis with polyangiitis (EGPA).
• Serologic Autoantibody Screen (Strict ANCA Negativity): Antineutrophil cytoplasmic antibodies (both indirect immunofluorescence and PR3/MPO enzyme-linked immunosorbent assays) are negative in classic PAN. Antinuclear antibodies (ANA) and rheumatoid factor (RF) are typically negative or present in low, non-specific titers. Serum complement levels (C3, C4) are normal in idiopathic PAN, but markedly depressed in active HBV-associated PAN.
• Infectious and Genetic Screening: Hepatitis B surface antigen (HBsAg), core antibody (anti-HBc IgM and IgG), and viral load (HBV DNA PCR) must be obtained in all patients prior to immunosuppressive therapy. Hepatitis C virus antibody and HIV serologies are mandatory. In pediatric or familial cases, plasma adenosine deaminase 2 activity and ADA2 gene sequencing should be performed.
• Renal Function and Urinalysis: Serum creatinine and blood urea nitrogen (BUN) assess ischemic renal impairment. Urinalysis demonstrates mild, non-nephrotic proteinuria (< 1.0 g/24h) and microhematuria. Dysmorphic red blood cells and red blood cell casts are absent, reflecting the non-glomerulonephritic nature of renal involvement.

Conventional and Cross-Sectional Angiography

Vascular imaging is indicated when tissue biopsy is technically unfeasible, non-diagnostic, or hazardous:

• Catheter-Directed Digital Subtraction Angiography (DSA): Conventional mesenteric, celiac, and renal DSA remains the gold standard imaging modality. It demonstrates the classic vascular triad: (1) multiple small saccular or fusiform microaneurysms measuring 1 to 5 mm in diameter arising predominantly at bifurcation points of medium muscular arteries, (2) alternating smooth luminal stenosis and post-stenotic ectasia ("string of beads"), and (3) abrupt arterial branch occlusions with delayed distal perfusion and peripheral wedge-shaped renal or hepatic parenchymal cortical defects.
• Computed Tomography Angiography (CTA) and Magnetic Resonance Angiography (MRA): High-resolution multi-detector CTA and contrast-enhanced MRA serve as excellent non-invasive alternatives. Modern 64-slice or dual-source CTA can resolve aneurysms down to 1.5 to 2.0 mm with high diagnostic accuracy. However, small intra-renal arcuate microaneurysms (< 1.5 mm) may fall below spatial resolution limits, rendering a negative CTA insufficient to exclude the diagnosis if clinical suspicion remains high.

Electromyography and Nerve Conduction Studies (EMG/NCS)

Electrodiagnostic testing is essential in any patient presenting with numbness, pain, or weakness. Nerve conduction studies demonstrate asymmetric, non-uniform sensorimotor axonal neuropathy characterized by markedly reduced compound muscle action potential (CMAP) and sensory nerve action potential (SNAP) amplitudes with preserved or mildly slowed conduction velocities. EMG confirms acute denervation potentials (fibrillations and positive sharp waves) in clinically and subclinically involved muscle distributions. Importantly, electrodiagnosis accurately localizes the optimal, actively denervated sural or superficial peroneal nerve segment for targeted surgical biopsy.

Histopathologic Biopsy Confirmation

Tissue biopsy demonstrating necrotizing arteritis provides definitive, incontrovertible confirmation. Biopsy should target clinically or electrodiagnostically symptomatic tissues:

• Combined Sural Nerve and Gastrocnemius Muscle Biopsy: In patients with peripheral neuropathy, simultaneous biopsy of the sural nerve and adjacent gastrocnemius muscle belly increases diagnostic yield to over 80%. Biopsying nerve alone carries a 20% to 30% false-negative rate because necrotizing lesions are highly segmental and skip normal vessel segments.
• Deep Full-Thickness Cutaneous Punch or Excisional Biopsy: Skin biopsy must include the full dermis and generous deep subcutaneous fat down to the deep fascia. Sampling only the superficial dermis yields non-specific perivascular infiltrate and misses the medium muscular arteries residing at the dermal-hypodermal junction. Biopsy of open ulcer centers must be avoided, as necrotic debris obscures vasculitic architecture; biopsy should target the active, indurated, violaceous border of an ulcer or an intact tender subcutaneous nodule.
• Testicular Biopsy: Unilateral wedge biopsy of a symptomatic, tender testicle provides a high diagnostic yield (> 90%) due to the dense medium-caliber muscular arborization of the testicular parenchyma, though it is reserved for cases where skin, muscle, or nerve biopsies are non-diagnostic.
• Pathologic Hallmarks: Transmural infiltration of the arterial wall by polymorphonuclear neutrophils, lymphocytes, and histiocytes; prominent fibrinoid necrosis of the tunica media; fragmentation of the internal elastic lamina (highlighted on elastin Verhoeff-Van Gieson stains); and luminal microthrombosis. The presence of lesions in varying stages of development (acute necrosis, reparative fibroblastic proliferation, and dense fibrous luminal scarring) within the same specimen strongly supports PAN.

7. Classification

Polyarteritis nodosa is formally classified using validated international consensus criteria and staged using validated prognostic scoring systems.

1990 American College of Rheumatology (ACR) Classification Criteria

The 1990 ACR criteria were established to differentiate polyarteritis nodosa from other forms of systemic vasculitis. A patient is classified as having PAN if at least 3 of the 10 criteria are met, conferring a sensitivity of 82.2% and a specificity of 86.6%.

2012 Revised Chapel Hill Consensus Conference (CHCC) Definitions

The revised 2012 CHCC consensus updated nomenclature to resolve classification ambiguities between PAN and microscopic polyangiitis (MPA). CHCC strictly defines polyarteritis nodosa as:

• Arterial Target Caliber: Necrotizing arteritis of medium- or small-sized muscular arteries.
• Microvascular Exclusion: Strict absence of glomerulonephritis or vasculitis in arterioles, capillaries, or venules.
• Serologic Exclusion: Sparing of ANCA association (ANCA-negative). The presence of PR3-ANCA or MPO-ANCA reclassifies the pathology as an ANCA-associated vasculitis regardless of arterial caliber.

Prognostic Risk Staging: The Five-Factor Score (FFS)

Validated by the French Vasculitis Study Group (Guillevin et al., 1996; revised 2011), the Five-Factor Score stratifies baseline mortality risk and directly dictates immunosuppressive treatment intensity:

8. Treatment

Modern management of polyarteritis nodosa requires a risk-stratified, multi-tiered medical regimen to induce and maintain remission, alongside disciplined conservative orthopaedic and interventional care.

Medical / Nonoperative Pharmacotherapy

Therapy is divided into remission-induction and remission-maintenance phases, stratified by disease severity and etiology:

• Non-Severe Idiopathic PAN (FFS = 0) – Corticosteroid Induction: Oral prednisone initiated at 1.0 mg/kg/day (maximum 60 to 80 mg/day) as a single morning dose. Maintain this dose for 3 to 4 weeks until clinical symptoms and inflammatory markers normalize, followed by a slow, structured taper over 6 to 12 months.
• Non-Severe Idiopathic PAN (FFS = 0) – Steroid-Sparing DMARD Therapy: Early adjunctive addition of oral methotrexate (20 to 25 mg/week with folic acid 1 to 5 mg/day) or oral azathioprine (2.0 mg/kg/day) is recommended to facilitate glucocorticoid tapering and prevent relapse.
• Severe / Organ-Threatening PAN (FFS ≥ 1) – Pulse Glucocorticoid Induction: Intravenous methylprednisolone 1,000 mg (or 15 mg/kg) infused over 60 minutes once daily for 3 consecutive days. Transition immediately on day 4 to oral prednisone 1.0 mg/kg/day.
• Severe / Organ-Threatening PAN (FFS ≥ 1) – Pulse Cyclophosphamide Therapy: Intravenous cyclophosphamide administered at 0.5 to 0.7 g/m² (adjusted for renal clearance) every 2 to 3 weeks for the first 3 doses, then every 3 to 4 weeks for a total of 6 pulses. Intravenous hydration and co-administration of sodium 2-mercaptoethanesulfonate (mesna) are mandatory to neutralize acrolein and prevent hemorrhagic cystitis. Oral cyclophosphamide (2.0 mg/kg/day) for 3 to 6 months represents an alternative.
• Severe / Organ-Threatening PAN (FFS ≥ 1) – Maintenance Transition: Following successful remission induction at 3 to 6 months, cyclophosphamide must be discontinued to minimize cumulative gonadotoxic, myelosuppressive, and urothelial oncogenic risks. Transition to maintenance therapy with oral azathioprine (2.0 mg/kg/day) or subcutaneous methotrexate (20 to 25 mg/week) for a minimum of 18 to 24 months.
• Hepatitis B Virus-Associated PAN – Antiviral Backbone: Potent oral nucleoside/nucleotide reverse transcriptase inhibitors with high genetic barriers to resistance, specifically entecavir (0.5 to 1.0 mg/day) or tenofovir disoproxil fumarate (300 mg/day), must be initiated immediately.
• Hepatitis B Virus-Associated PAN – Short-Course Glucocorticoids & Plasma Exchange: Glucocorticoids are restricted to a brief 2- to 3-week taper solely to suppress life-threatening acute vasculitic inflammation while antivirals take effect. Cyclophosphamide is strictly avoided, as profound immunosuppression stimulates explosive HBV replication, leading to fulminant hepatic necrosis. In severe cases, plasmapheresis (plasma exchange 2 to 3 times weekly for 2 to 3 weeks) rapidly clears circulating HBsAg-anti-HBs immune complexes.
• Infection Prophylaxis: Trimethoprim-sulfamethoxazole (TMP-SMX 80/400 mg single strength daily or 160/800 mg double strength 3 times weekly) is mandatory throughout cyclophosphamide therapy and high-dose glucocorticoid administration to prevent Pneumocystis jirovecii pneumonia.
• Bone Protection: Daily elemental calcium (1,000 to 1,200 mg), vitamin D3 (800 to 2,000 IU), and oral bisphosphonate therapy (e.g., alendronate 70 mg weekly) to counteract rapid glucocorticoid-induced bone loss.
• Antihypertensive Optimization: Aggressive blood pressure control targeting < 130/80 mmHg using calcium channel blockers and beta-blockers. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) must be utilized with extreme caution and close creatinine surveillance, as bilateral renal artery microaneurysms or severe stenosis can precipitate precipitous renal failure.

Operative Interventions and Orthopaedic Management

Surgical intervention in polyarteritis nodosa is highly specialized and strictly defined by acute indications:

• Catheter-Directed Transcatheter Arterial Embolization (TAE): TAE is the treatment of choice for acute retroperitoneal or intraperitoneal hemorrhage resulting from ruptured renal, hepatic, or mesenteric microaneurysms. Selective microcatheter super-selection of the bleeding branch followed by deployment of microcoils or liquid embolic agents (N-butyl cyanoacrylate, ethylene vinyl alcohol copolymer) achieves rapid hemostasis without the catastrophic failure rates of open surgical dissection in friable, necrotic retroperitoneal tissue.
• Acute Surgical Abdomen: Emergent exploratory laparotomy is indicated for frank gastrointestinal perforation, bowel infarction with peritonitis, or acute cholecystitis/appendicitis. Intestinal resection must extend back to visibly bleeding, well-perfused bowel margins. Primary anastomoses carry an extreme risk of dehiscence due to ongoing microvascular ischemia; exteriorization with temporary stoma creation is the safest surgical approach.
• Acutely Ischemic Digits and Acral Extremities: Dry gangrene of fingers or toes should be managed nonoperatively with dry antiseptic dressings, digital protection, and systemic immunosuppression. Premature surgical debridement or amputation through actively inflamed tissues triggers proximal tissue loss and flap necrosis. Amputation should be delayed until the patient achieves systemic clinical remission and dry gangrene exhibits clear, unequivocal demarcation.
• Orthopaedic Management of Mononeuritis Multiplex: During the acute and subacute phases, treatment focuses on conservative splinting and physical therapy. Patients with common peroneal nerve infarction causing foot drop require custom rigid or articulated ankle-foot orthoses (AFO) to prevent equinovarus contracture and optimize ambulation. Wrist drop requires a volar cock-up splint. Reconstructive tendon transfers (e.g., posterior tibial tendon transfer through the interosseous membrane to the lateral cuneiform and cuboid) are strictly contraindicated during active disease and should be considered only after at least 18 to 24 months of stable clinical remission with complete plateau of spontaneous neural recovery.

Indications & Contraindications Matrix

9. Outcome

Modern clinical outcomes in polyarteritis nodosa reflect the balance between aggressive immunosuppressive control of active vascular inflammation and the avoidance of fatal therapeutic toxicities.

Survival and Remission Rates

In contemporary clinical cohorts managed with combined corticosteroid and cyclophosphamide protocols, remission induction is achieved in 85% to 90% of patients within 6 months. Overall 5-year survival is 80% to 85%, and 10-year survival is 72% to 78%. In the prospective French Vasculitis Study Group CHUSPAN trials, 10-year survival in poor-prognosis PAN (FFS ≥ 1) treated with pulse cyclophosphamide and corticosteroids reached 72.8%. Independent predictors of long-term mortality include initial presentation with FFS ≥ 2, age > 65 years, and severe gastrointestinal involvement.

Neurologic and Functional Recovery

Recovery from vasculitic mononeuritis multiplex is notoriously slow and often incomplete. Axonal regeneration occurs at approximately 1 mm per day. Although sensory dysesthesias improve within weeks to months following inflammatory suppression, motor deficits (severe foot drop or hand intrinsic weakness) require 12 to 24 months of prolonged rehabilitation. Approximately 30% to 40% of patients harbor permanent, residual mild-to-moderate motor or sensory deficits that necessitate permanent orthotic use. Patient-reported outcome measures, including the Short Form-36 (SF-36) and Health Assessment Questionnaire (HAQ), demonstrate marked functional recovery that plateaus at approximately 18 months, with physical function scores closely paralleling the severity of initial neurologic damage.

10. Complications

Complications in polyarteritis nodosa stem from two distinct sources: unchecked ischemic vascular destruction caused by the underlying vasculitis, and iatrogenic toxicities resulting from intense cytotoxic and immunosuppressive regimens.

11. Pearls and Pitfalls

Mastery of polyarteritis nodosa requires recognizing subtle diagnostic clues while navigating high-risk diagnostic and surgical traps.

Clinical and Diagnostic Pearls

• The Combined Muscle-Nerve Biopsy Advantage: Never biopsy the sural nerve alone in suspected mononeuritis multiplex. Combining the sural nerve biopsy with an open biopsy of the adjacent peroneus brevis or medial gastrocnemius muscle belly increases diagnostic sensitivity by over 30%, as vasculitic involvement of intramuscular arterioles is frequently more diffuse than that of the nerve trunk itself.
• The Testicular Tenderness Clue: In adult males presenting with fever of unknown origin, unexplained weight loss, and myalgias, systematically palpate the testicles. Unilateral testicular tenderness without infectious signs is an extraordinarily high-yield clinical finding that strongly suggests PAN and provides an accessible site for biopsy.
• Mandatory Hepatitis B Testing: Always obtain HBsAg and anti-HBc before starting cyclophosphamide. Treating HBV-associated PAN with cytotoxic cyclophosphamide without antiviral therapy can trigger explosive viral replication and fatal fulminant hepatic necrosis.
• The Pulmonary Exemption Rule: If a patient with suspected PAN presents with pulmonary infiltrates, cavitary lung nodules, or alveolar hemorrhage, pause immediately: this is virtually never PAN. Re-test for ANCA and investigate for microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA).

Surgical and Management Pitfalls

• The Amputation Rush Trap: Do not perform early digital amputations or debridement in patients presenting with blackened, ischemic fingertips or toes during acute systemic PAN. Once high-dose corticosteroid and cyclophosphamide therapy halts microvascular inflammation, marginal ischemic tissues frequently reperfuse, substantially reducing the ultimate amputation level.
• The Vascular Suture Failure Trap: Avoid open vascular reconstructive bypass grafting across actively inflamed, necrotizing arterial segments. Suture lines pull through friable, necrotic vessel walls, causing catastrophic anastomotic dehiscence, secondary pseudoaneurysms, and fatal exsanguination. Rely on endovascular coil or particulate embolization for active bleeding.
• The Premature Tendon Transfer Trap: Do not operate to correct foot drop within the first 12 to 18 months of illness onset. Axonal regeneration through the long peroneal nerve corridor requires up to two years. Premature tendon transfer risks operating during an active disease flare and sacrificing dynamic muscle units that may have recovered spontaneously.
• The Superficial Punch Biopsy Trap: Never perform a standard 2 mm superficial epidermal punch biopsy when evaluating livedo reticularis or cutaneous nodules for PAN. The affected medium muscular vessels reside deep within the subcutaneous adipose tissue at the dermal-hypodermal junction. Always perform a generous wedge excision or deep 6 mm punch down to the deep fascia.

12. Controversy

Several clinical and scientific controversies surround the contemporary classification and management of polyarteritis nodosa.

Biologic Targeted Therapies in Refractory PAN

While targeted biologic agents such as rituximab (anti-CD20) have revolutionized the treatment of ANCA-associated vasculitides, their role in primary idiopathic polyarteritis nodosa remains unproven and controversial. Because classic PAN is mediated predominantly by immune complex deposition, T-cell infiltration, and neutrophilic necrotizing damage rather than direct ANCA-mediated pathogenicity, prospective randomized trials of rituximab in PAN are lacking. In patients refractory to cyclophosphamide, tumor necrosis factor-alpha (TNF-alpha) inhibitors (e.g., infliximab, adalimumab, etanercept) and interleukin-6 receptor antagonists (tocilizumab) have shown promising results in small observational cohorts, but high-quality randomized evidence is absent.

Deficiency of Adenosine Deaminase 2 (DADA2) Paradigm

The discovery of loss-of-function mutations in the ADA2 gene (formerly CECR1) has established that a substantial fraction of pediatric-onset and early-adulthood PAN cases represent monogenic autoinflammatory deficiency of adenosine deaminase 2 (DADA2). Patients present with systemic PAN-like vasculitis, livedo reticularis, early-onset lacunar and ischemic strokes, and immunodeficiency. Crucially, DADA2 is notoriously resistant to conventional cyclophosphamide and glucocorticoids, but exhibits dramatic, life-saving responsiveness to TNF-alpha inhibitors. Whether all young adults presenting with PAN should undergo mandatory genetic screening for DADA2 prior to cytotoxic chemotherapy remains an active clinical consensus debate.

Duration of Maintenance Immunosuppression

The optimal duration of maintenance immunosuppression in idiopathic PAN remains contentious. While historical protocols discontinued maintenance therapy at 12 to 18 months following remission, contemporary registry studies demonstrate a cumulative 5-year relapse rate approaching 25% to 30%. Many expert consensus groups advocate extending maintenance therapy with azathioprine or methotrexate to 24 to 36 months, particularly in patients presenting initially with high-risk Five-Factor Score features or persistent elevation in acute-phase reactants.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Chung SA, Gorelik M, Langford CA et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Care Res (Hoboken). 2021. doi:10.1002/acr.24633 [Level I: Systematic Review & Clinical Practice Guideline]
• Samson M, Puéchal X, Mouthon L et al. Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. Clin Exp Rheumatol. 2017. doi:PMID:28422001 [Level I: Randomized Controlled Trial]
• Lightfoot RW Jr, Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990. doi:10.1002/art.1780330805 [Level II: Prospective Multicenter Classification Validation Study]
• Guillevin L, Lhote F, Gayraud M et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996. doi:10.1097/00005792-199601000-00003 [Level II: Prospective Multicenter Prognostic Validation Study]
• Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013. doi:10.1002/art.37715 [Level V: International Consensus Panel Definition]

15. Master Class Pro-Tip

When evaluating severe lower extremity ischemic pain or sudden asymmetric foot drop in a patient with constitutional decline, suspect systemic necrotizing vasculitis and resist the urge to perform urgent surgical decompression or blind revascularization across acutely inflamed arterial beds. Suture retention failure and catastrophic anastomotic pseudoaneurysms are nearly universal in friable, necrotic vessel walls. Instead, obtain prompt visceral/renal catheter angiography or targeted full-thickness muscle/nerve biopsy from an electrodiagnostically abnormal site, initiate high-dose pulse methylprednisolone and cyclophosphamide without delay, and defer any surgical debridement of dry gangrenous digits until systemic inflammation is controlled and clear tissue demarcation occurs.

Master Class Surgical Pearl: Avoiding Revascularization Traps and Optimizing Biopsy Yield in Necrotizing Arteritis